125 материалов по теме, собраны автоматически из проверенных источников
New Clinical Trial Combines Histotripsy with Immunotherapy to Treat Intrahepatic Bile Duct Cancer | Newswise Newswise
Gut Bacteria and Diet May Explain Why Obesity Sometimes Boosts Cancer Immunotherapy Bioengineer.org
Manushak Avagyan: Neoadjuvant Immunotherapy Is Here to Stay Oncodaily
Mashukur Rahman: Narrative Review on Endocrine Complications of Cancer Immunotherapy Oncodaily
Julia Gray: Beginning a New Chapter at the Parker Institute for Cancer Immunotherapy to Accelerate Cancer Research Oncodaily
A new study published in Nature Aging combines mouse experiments and human data sets to explore how biological sex and aging shape cancer immunity, with implications for immunotherapy responses. Lutz Menzel, Ph.D., formerly of the Department of Radiation Oncology within the Mass General Brigham Cancer Institute, is…
Susanna Fletcher Greer։ V Foundation-Funded Scientists Explore Advances in Cancer Immunotherapy and Personalized Treatment Oncodaily
Wistar Scientists Uncover Two-Pronged Strategy to Overcome Glioblastoma’s Resistance to Immunotherapy | Newswise Newswise
A research team has developed a combination immunotherapy that uses an electrical ablation technique to enhance the efficacy of immune cell therapy against liver cancer.
WMA GmbH – 13th Immunotherapy of Cancer Conference (ITOC13) Oncodaily
Scientists at The Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. In a study published in Neuro-Oncology, the researchers show that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect…
Surgical volume could be reduced for patients with locally advanced head and neck squamous cell carcinoma who respond to neoadjuvant chemoimmunotherapy. Data from a phase 2 trial showed individuals with HPV-negative disease, who achieved at least a 50% reduction in primary tumor burden after neoadjuvant treatment, and…
Launching Hope Through an Innovative Immunotherapy University of Utah Health
Новые перспективы в лечении трижды негативного рака молочной железы с помощью иммунотерапии. Vietnam.vn
A randomized phase 2B trial of a novel peptide-based vaccine missed its primary endpoint, as the immunotherapy failed to significantly extend survival compared with placebo in newly diagnosed glioblastoma, according to a press release. However, topline data showed SurVaxM (MimiVax Inc.) may have the potential to delay…